Minireview: The versatile roles of lysine deacetylases in steroid receptor signaling

Molecular Endocrinology

Volumn 28, Issue 5, 2014, Pages 607-621

  Kadiyala, Vineela ^a   Smith, Catharine L ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APICIDIN; BUTYRIC ACID; CELL NUCLEUS RECEPTOR; CHAPERONE; DEXAMETHASONE; DNA; ESTROGEN RECEPTOR ALPHA; GELDANAMYCIN; GLUCOCORTICOID RECEPTOR; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; LYSINE DEACETYLASE; MINERALOCORTICOID RECEPTOR; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; ROMIDEPSIN; SMALL INTERFERING RNA; STEROID RECEPTOR; THYROID HORMONE RECEPTOR; TRANSCRIPTION FACTOR CLOCK; TRANSCRIPTOME; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; DNA BINDING; ENZYME ACTIVITY; GENE ACTIVATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HORMONE RECEPTOR INTERACTION; HUMAN; HYPERTENSION; LIGAND BINDING; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; TRANSACTIVATION; ANIMAL; GENETIC EPIGENESIS; METABOLISM; PHYSIOLOGY; PROTEIN PROCESSING; SIGNAL TRANSDUCTION;

ACETYLATION; ANIMALS; EPIGENESIS, GENETIC; HISTONE DEACETYLASES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, STEROID; SIGNAL TRANSDUCTION;

EID: 84899728422     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2014-1002     Document Type: Review

References (125)

1. Kuo MH, Brownell JE, Sobel RE, et al. Transcription-linked acetylation by Gcn5p of histones H3 and H4 at specific lysines. Nature. 1996; 383: 269-272.
2. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell. 1996; 87: 953-959.
3. Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science. 1996; 272: 408-411.
4. Rundlett SE, Carmen AA, Kobayashi R, Bavykin S, Turner BM, Grunstein M. HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes that regulate silencing and transcription. Proc Natl Acad Sci USA. 1996; 93: 14503-14508.
5. De Rubertis F, Kadosh D, Henchoz S, et al. The histone deacetylase RPD3 counteracts genomic silencing in Drosophila and yeast. Nature. 1996; 384: 589-591.
6. Phillips DM. The presence of acetyl groups of histones. Biochem J. 1963; 87: 258-263.
7. Turner BM. Histone acetylation and control of gene expression. J Cell Sci. 1991; 99: 13-20.
8. Kuo MH, Allis CD. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays. 1998; 20: 615-626.
9. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009; 10: 32-42.
10. Smith CL. Ashifting paradigm: histone deacetylases and transcriptional activation. Bioessays. 2008; 30: 15-24.
11. Xu M, Nie L, Kim SH, Sun XH. STAT5-induced Id-1 transcription involves recruitment of HDAC1 and deacetylation of C/EBPβ. EMBO J. 2003; 22: 893-904.
12. Ziesché E, Kettner-Buhrow D, Weber A, et al. The coactivator role of histone deacetylase 3 in IL-1-signaling involves deacetylation of p65 NF-κB. Nucleic Acids Res. 2013; 41: 90-109.
13. Klampfer L, Huang J, Swaby LA, Augenlicht L. Requirement of histone deacetylase activity for signaling by STAT1. J Biol Chem. 2004; 279: 30358-30368.
14. Rascle A, Johnston JA, Amati B. Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. Mol Cell Biol. 2003; 23: 4162-4173.
15. Wang Z, Zang C, Cui K, et al. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell. 2009; 138: 1019-1031.
16. Kidder BL, Palmer S. HDAC1 regulates pluripotency and lineage specific transcriptional networks in embryonic and trophoblast stem cells. Nucleic Acids Res. 2012; 40: 2925-2939.
17. Ram O, Goren A, Amit I, et al. Combinatorial patterning of chromatin regulators uncovered by genome-wide location analysis in human cells. Cell. 2011; 147: 1628-1639.
18. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 1997; 90: 595-606.
19. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene. 2005; 363: 15-23.
20. Kim SC, Sprung R, Chen Y, et al. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell. 2006; 23: 607-618.
21. Choudhary C, Kumar C, Gnad F, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009; 325: 834-840.
22. Huang B, Yang XD, Zhou MM, Ozato K, Chen LF. Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol Cell Biol. 2009; 29: 1375-1387.
23. Zou Z, Huang B, Wu X, et al. Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA [published online May 20, 2013]. Oncogene. doi: 10. 1038/onc. 2013. 179.
24. Yang XD, Tajkhorshid E, Chen LF. Functional interplay between acetylation and methylation of the RelA subunit of NF-κB. Mol Cell Biol. 2010; 30: 2170-2180.
25. Kiernan R, Brès V, Ng RW, et al. Post-activation turn-off of NF-κ B-dependent transcription is regulated by acetylation of p65. J Biol Chem. 2003; 278: 2758-2766.
26. Lallemand F. Direct inhibition of the expression of cyclin D1 gene by sodium butyrate. Biochem Biophys Res Commun. 1996; 229: 163-169.
27. Polack A, Eick D, Koch E, Bornkamm GW. Truncation does not abrogate transcriptional downregulation of the c-myc gene by sodium butyrate in Burkitt's lymphoma cells. EMBO J. 1987; 6: 2959-2964.
28. Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 1996; 5: 245-253.
29. Peart MJ, Smyth GK, van Laar RK, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A. 2005; 102: 3697-3702.
30. Mulholland NM, Soeth E, Smith CL. Inhibition of MMTV transcription by HDAC inhibitors occurs independent of changes in chromatin remodeling and increased histone acetylation. Oncogene. 2003; 22: 4807-4818.
31. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol. 1997; 11: 693-705.
32. Wagner BL, Norris JD, Knotts TA, Weigel NL, McDonnell DP. The nuclear corepressors NCoR and SMRT are key regulators of both ligand-and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. Mol Cell Biol. 1998; 18: 1369-1378.
33. Lavinsky RM, Jepsen K, Heinzel T, et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A. 1998; 95: 2920-2925.
34. Robyr D, Wolffe AP, Wahli W. Nuclear hormone receptor coregulators in action: diversity for shared tasks. Mol Endocrinol. 2000; 14: 329-347.
35. Jepsen K, Rosenfeld MG. Biological roles and mechanistic actions of co-repressor complexes. J Cell Sci. 2002; 115: 689-698.
36. Jones PL, Shi YB. N-CoR-HDAC corepressor complexes: roles in transcriptional regulation by nuclear hormone receptors. Curr Top Microbiol Immunol. 2003; 274: 237-268.
37. Tichonicky L, Santana-Calderon MA, Defer N, Giesen EM, Beck G, Kruh J. Selective inhibition by sodium butyrate of glucocorticoid-induced tyrosine aminotransferase synthesis in hepatoma tissue-cultured cells. Eur J Biochem. 1981; 120: 427-433.
38. Plesko MM, Hargrove JL, Granner DK, Chalkley R. Inhibition by sodium butyrate of enzyme induction by glucocorticoids and dibutyryl cyclic AMP. A role for the rapid form of histone acetylation. J Biol Chem. 1983; 258: 13738-13744.
39. McKnight GS, Hager L, Palmiter RD. Butyrate and related inhibitors of histone deacetylation block the induction of egg white genes by steroid hormones. Cell. 1980; 22: 469-477.
40. Bresnick EH, John S, Berard DS, LeFebvre P, Hager GL. Glucocorticoid receptor-dependent disruption of a specific nucleosome on the mouse mammary tumor virus promoter is prevented by sodium butyrate. Proc Natl Acad Sci USA. 1990; 87: 3977-3981.
41. Johnson JL, Toft DO. Binding of p23 and hsp90 during assembly with the progesterone receptor. Mol Endocrinol. 1995; 9: 670-678.
42. Whitesell L, Cook P. Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells. Mol Endocrinol. 1996; 10: 705-712.
43. Fliss AE, Benzeno S, Rao J, Caplan AJ. Control of estrogen receptor ligand binding by Hsp90. J Steroid Biochem Mol Biol. 2000; 72: 223-230.
44. Kovacs JJ, Cohen TJ, Yao TP. Chaperoning steroid hormone signaling via reversible acetylation. Nucl Recept Signal. 2005; 3: e004.
45. Aoyagi S, Archer TK. Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends Cell Biol. 2005; 15: 565-567.
46. Kovacs JJ, Murphy PJ, Gaillard S, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell. 2005; 18: 601-607.
47. Zhang Y, Kwon S, Yamaguchi T, et al. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol. 2008; 28: 1688-1701.
48. Gibbs A, Schwartzman J, Deng V, Alumkal J. Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc Natl Acad Sci U S A. 2009; 106: 16663-16668.
49. Ai J, Wang Y, Dar JA, et al. HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer. Mol Endocrinol. 2009; 23: 1963-1972.
50. Fiskus W, Ren Y, Mohapatra A, et al. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-α levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res. 2007; 13: 4882-4890.
51. Aoyagi S, Archer TK. Dynamic histone acetylation/deacetylation with progesterone receptor-mediated transcription. Mol Endocrinol. 2007; 21: 843-856.
52. Kim SH, Kang HJ, Na H, Lee MO. Trichostatin A enhances acetylation as well as protein stability of ERα through induction of p300 protein. Breast Cancer Res. 2010; 12: R22.
53. Kadiyala V, Patrick NM, Mathieu W, et al. Class I Lysine Deacetylases Facilitate Glucocorticoid-induced Transcription. J Biol Chem. 2013; 288: 28900-28912.
54. Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res. 2002; 8: 718-728.
55. Marshall JL, Rizvi N, Kauh J, et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol. 2002; 2: 325-332.
56. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005; 23: 3923-3931.
57. Bartsch J, Truss M, Bode J, Beato M. Moderate increase in histone acetylation activates the mouse mammary tumor virus promoter and remodels its nucleosome structure. Proc Natl Acad Sci USA. 1996; 93: 10741-10746.
58. Chng KR, Chang CW, Tan SK, et al. A transcriptional repressor co-regulatory network governing androgen response in prostate cancers. EMBO J. 2012; 31: 2810-2823.
59. Korkmaz CG, Frønsdal K, Zhang Y, Lorenzo PI, Saatcioglu F. Potentiation of androgen receptor transcriptional activity by inhibition of histone deacetylation-rescue of transcriptionally compromised mutants. J Endocrinol. 2004; 182: 377-389.
60. Bantscheff M, Hopf C, Savitski MM, et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol. 2011; 29: 255-265.
61. Archer TK, Lefebvre P, Wolford RG, Hager GL. Transcription factor loading on theMMTVpromoter: A bimodal mechanism for promoter activation. Science. 1992; 255: 1573-1576.
62. Lambert JR, Nordeen SK. Steroid-selective initiation of chromatin remodeling and transcriptional activation of the mouse mammary tumor virus promoter is controlled by the site of promoter integration. J Biol Chem. 1998; 273: 32708-32714.
63. Lee SC, Magklara A, Smith CL. HDAC activity is required for efficient core promoter function at the mouse mammary tumor virus promoter. J Biomed Biotechnol. 2011; 2011: 416905.
64. Qiu Y, Stavreva DA, Luo Y, Indrawan A, Chang M, Hager GL. Dynamic interaction of HDAC1 with a glucocorticoid receptor regulated gene is modulated by the activity state of the promoter. J Biol Chem. 2011; 286: 7641-7647.
65. Luo Y, Jian W, Stavreva D, et al. Trans-regulation of histone deacetylase activities through acetylation. J Biol Chem. 2009; 284: 34901-34910.
66. Qiu Y, Zhao Y, Becker M, et al. HDAC1 acetylation is linked to progressive modulation of steroid receptor-induced gene transcription. Mol Cell. 2006; 22: 669-679.
67. Sheldon LA, Becker M, Smith CL. Steroid hormone receptor-mediated histone deacetylation and transcription at the mouse mammary tumor virus promoter. J Biol Chem. 2001; 276: 32423-32426.
68. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol. 2008; 9: 206-218.
69. Jurkin J, Zupkovitz G, Lagger S, et al. Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis. Cell Cycle. 2011; 10: 406-412.
70. Guan JS, Haggarty SJ, Giacometti E, et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature. 2009; 459: 55-60.
71. Chinenov Y, Gupte R, Rogatsky I. Nuclear receptors in inflammation control: Repression by GR and beyond. Mol Cell Endocrinol. 2013; 380: 55-64.
72. Nissen RM, Yamamoto KR. The glucocorticoid receptor inhibits NFκB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev. 2000; 14: 2314-2329.
73. Kassel O, Herrlich P. Crosstalk between the glucocorticoid receptor and other transcription factors: molecular aspects. Mol Cell Endocrinol. 2007; 275: 13-29.
74. Lemke U, Krones-Herzig A, Berriel Diaz M, et al. The glucocorticoid receptor controls hepatic dyslipidemia through Hes1. Cell Metab. 2008; 8: 212-223.
75. Uhlenhaut NH, Barish GD, Yu RT, et al. Insights into negative regulation by the glucocorticoid receptor from genome-wide profiling of inflammatory cistromes. Mol Cell. 2013; 49: 158-171.
76. Surjit M, Ganti KP, Mukherji A, et al. Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor. Cell. 2011; 145: 224-241.
77. Chen Y, Watson AM, Williamson CD, et al. Glucocorticoid receptor and histone deacetylase-2 mediate dexamethasone-induced repression of MUC5AC gene expression. Am J Respir Cell Mol Biol. 2012; 47: 637-644.
78. Bilodeau S, Vallette-Kasic S, Gauthier Y, et al. Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev. 2006; 20: 2871-2886.
79. Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1β-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol. 2000; 20: 6891-6903.
80. Ito K, Yamamura S, Essilfie-Quaye S, et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med. 2006; 203: 7-13.
81. Wang C, Tian L, Popov VM, Pestell RG. Acetylation and nuclear receptor action. J Steroid Biochem Mol Biol. 2011; 123: 91-100.
82. Anbalagan M, Huderson B, Murphy L, Rowan BG. Post-translational modifications of nuclear receptors and human disease. Nucl Recept Signal. 2012; 10: e001.
83. Nader N, Chrousos GP, Kino T. Circadian rhythm transcription factor CLOCK regulates the transcriptional activity of the glucocorticoid receptor by acetylating its hinge region lysine cluster: potential physiological implications. FASEB J. 2009; 23: 1572-1583.
84. Charmandari E, Chrousos GP, Lambrou GI, et al. Peripheral CLOCK regulates target-tissue glucocorticoid receptor transcriptional activity in a circadian fashion in man. PLoS One. 2011; 6: e25612.
85. Welsbie DS, Xu J, Chen Y, et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrateresistant prostate cancer. Cancer Res. 2009; 69: 958-966.
86. List HJ, Smith CL, Rodriguez O, Danielsen M, Riegel AT. Inhibition of histone deacetylation augments dihydrotestosterone induction of androgen receptor levels: an explanation for trichostatin A effects on androgen-induced chromatin remodeling and transcription of the mouse mammary tumor virus promoter. Exp Cell Res. 1999; 252: 471-478.
87. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005; 310: 644-648.
88. Fu M, Wang C, Reutens AT, et al. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem. 2000; 275: 20853-20860.
89. Tanner TM, Denayer S, Geverts B, et al. A 629RKLKK633 motif in the hinge region controls the androgen receptor at multiple levels. Cell Mol Life Sci. 2010; 67: 1919-1927.
90. Cutress ML, Whitaker HC, Mills IG, Stewart M, Neal DE. Structural basis for the nuclear import of the human androgen receptor. J Cell Sci. 2008; 121: 957-968.
91. Shiota M, Yokomizo A, Masubuchi D, et al. Tip60 promotes prostate cancer cell proliferation by translocation of androgen receptor into the nucleus. Prostate. 2010; 70: 540-554.
92. Thomas M, Dadgar N, Aphale A, et al. Androgen receptor acetylation site mutations cause trafficking defects, misfolding, and aggregation similar to expanded glutamine tracts. J Biol Chem. 2004; 279: 8389-8395.
93. Faus H, Haendler B. Androgen receptor acetylation sites differentially regulate gene control. J Cell Biochem. 2008; 104: 511-524.
94. Gaughan L, Logan IR, Cook S, Neal DE, Robson CN. Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J Biol Chem. 2002; 277: 25904-25913.
95. Fu M, Rao M, Wang C, et al. Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol. 2003; 23: 8563-8575.
96. Haelens A, Tanner T, Denayer S, Callewaert L, Claessens F. The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor. Cancer Res. 2007; 67: 4514-4523.
97. Gaughan L, Stockley J, Wang N, et al. Regulation of the androgen receptor by SET9-mediated methylation. Nucleic Acids Res. 2011; 39: 1266-1279.
98. Fu M, Wang C, Wang J, et al. Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function. Mol Cell Biol. 2002; 22: 3373-3388.
99. Ko S, Ahn J, Song CS, Kim S, Knapczyk-Stwora K, Chatterjee B. Lysine methylation and functional modulation of androgen receptor by Set9 methyltransferase. Mol Endocrinol. 2011; 25: 433-444.
100. Yang X, Ferguson AT, Nass SJ, et al. Transcriptional activation of estrogen receptor α in human breast cancer cells by histone deacetylase inhibition. Cancer Res. 2000; 60: 6890-6894.
101. Alao JP, Lam EW, Ali S, et al. Histone deacetylase inhibitor trichostatin A represses estrogen receptor α-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin Cancer Res. 2004; 10: 8094-8104.
102. Reid G, Métivier R, Lin CY, et al. Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor α, in response to deacetylase inhibition by valproic acid and trichostatin A. Oncogene. 2005; 24: 4894-4907.
103. Biçaku E, Marchion DC, Schmitt ML, Münster PN. Selective inhibition of histone deacetylase 2 silences progesterone receptormediated signaling. Cancer Res. 2008; 68: 1513-1519.
104. Kim MY, Woo EM, Chong YT, Homenko DR, Kraus WL. Acetylation of estrogen receptor α by p300 at lysines 266 and 268 enhances the deoxyribonucleic acid binding and transactivation activities of the receptor. Mol Endocrinol. 2006; 20: 1479-1493.
105. Wang C, Fu M, Angeletti RH, et al. Direct acetylation of the estrogen receptor α hinge region by p300 regulates transactivation and hormone sensitivity. J Biol Chem. 2001; 276: 18375-18383.
106. Ma Y, Fan S, Hu C, et al. BRCA1 regulates acetylation and ubiquitination of estrogen receptor-α. Mol Endocrinol. 2010; 24: 76-90.
107. Le Romancer M, Poulard C, Cohen P, Sentis S, Renoir JM, Corbo L. Cracking the estrogen receptor's posttranslational code in breast tumors. Endocr Rev. 2011; 32: 597-622.
108. Chen H, Lin RJ, Xie W, Wilpitz D, Evans RM. Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell. 1999; 98: 675-686.
109. Wilson MA, Ricci AR, Deroo BJ, Archer TK. The histone deacetylase inhibitor trichostatin A blocks progesterone receptor-mediated transactivation of the mouse mammary tumor virus promoter in vivo. J Biol Chem. 2002; 277: 15171-15181.
110. Narayanan R, Edwards DP, Weigel NL. Human progesterone receptor displays cell cycle-dependent changes in transcriptional activity. Mol Cell Biol. 2005; 25: 2885-2898.
111. Mymryk JS, Berard D, Hager GL, Archer TK. Mouse mammary tumor virus chromatin in human breast cancer cells is constitutively hypersensitive and exhibits steroid hormone-independent loading of transcription factors in vivo. Mol Cell Biol. 1995; 15: 26-34.
112. Cato AC, Henderson D, Ponta H. The hormone response element of the mouse mammary tumour virus DNA mediates the progestin and androgen induction of transcription in the proviral long terminal repeat region. EMBO J. 1987; 6: 363-368.
113. Daniel AR, Gaviglio AL, Czaplicki LM, Hillard CJ, Housa D, Lange CA. The progesterone receptor hinge region regulates the kinetics of transcriptional responses through acetylation, phosphorylation, and nuclear retention. Mol Endocrinol. 2010; 24: 2126-2138.
114. Cardinale JP, Sriramula S, Pariaut R, et al. HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension. 2010; 56: 437-444.
115. Lee HA, Lee DY, Cho HM, Kim SY, Iwasaki Y, Kim I. Histone deacetylase inhibition attenuates transcriptional activity of mineralocorticoid receptor through its acetylation and prevents development of hypertension. Circ Res. 2013; 112: 1004-1012.
116. Jang ER, Lim SJ, Lee ES, et al. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor α-negative breast cancer cells to tamoxifen. Oncogene. 2004; 23: 1724-1736.
117. Zhou Q, Agoston AT, Atadja P, Nelson WG, Davidson NE. Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol Cancer Res. 2008; 6: 873-883.
118. Defranco DB, Madan AP, Tang Y, Chandran UR, Xiao N, Yang J. Nucleocytoplasmic shuttling of steroid receptors. Vitam Horm. 1995; 51: 315-338.
119. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell. 2000; 103: 843-852.
120. Métivier R, Penot G, Hübner MR, et al. Estrogen receptor-α directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell. 2003; 115: 751-763.
121. John S, Johnson TA, Sung MH, et al. Kinetic complexity of the global response to glucocorticoid receptor action. Endocrinology. 2009; 150: 1766-1774.
122. Won Jeong K, Chodankar R, Purcell DJ, Bittencourt D, Stallcup MR. Gene-specific patterns of coregulator requirements by estrogen receptor-α in breast cancer cells. Mol Endocrinol. 2012; 26: 955-966.
123. Isojärvi JI, Taubøll E, Herzog AG. Effect of antiepileptic drugs on reproductive endocrine function in individuals with epilepsy. CNS Drugs. 2005; 19: 207-223.
124. Luef G, Rauchenzauner M, Waldmann M, et al. Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment. Epilepsy Res. 2009; 86: 42-47.
125. Tang J, Yan H, Zhuang S. Histone deacetylases as targets for treatment of multiple diseases. Clin Sci (Lond). 2013; 124: 651-662.